A multicenter phase I–II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer
- Resource Type
- Article
- Source
- In
The Breast December 2013 22(6):1171-1177 - Subject
- Language
- ISSN
- 0960-9776